- Net sales of DARZALEX® in the third quarter of 2020 totaled USD 1,099 million
- Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
Copenhagen, Denmark; October 13, 2020 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous formulation (sold under the tradename DARZALEX FASPROTM in the U.S.), as reported by Johnson & Johnson were USD 1,099 million in the third quarter of 2020. Net trade sales were USD 585 million in the U.S. and USD 514 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX and DARZALEX FASPRO under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize daratumumab. As previously announced, Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab’s share of Janssen’s royalty payments to Halozyme, cf. company announcement No. 39 of September 22, 2020.